Nanogel of Lollipop Leave Extract: A Promising Antibiofilm Agent for Diabetic Ulcer Infections

Treatment of diabetic ulcers presents a considerable healthcare obstacle due to their susceptibility to infection by antibiotic-resistant bacteria that may develop a long-lasting biofilm. The development of bacterial resistance to antimicrobial drugs significantly impacts the process of wound healing and poses a potential risk to both human life and the economy. To overcome this challenge, the integration of the antibacterial properties of lollipop leaf extract with a nanogel delivery technology has the potential to provide a new treatment strategy for addressing biofilm-related infection in diabetic ulcers. Therefore, this study aims to assess the capacity of lollipop leaf extract nanogel to expedite the process of wound healing in diabetic ulcers. The materials used were first subjected to a 5-day extraction process using 96% ethanol. To evaluate the antibacterial effectiveness, microdilution and well methods were used for the mid-phase, maturation phase, and eradication stages. Antibiofilm analysis was then conducted in vivo using adult mice that were induced with type II diabetes. The results showed that at a concentration of 30% w/v, lolipop-derived nanogel extract (LDNE) exhibited potent antibiofilm activity against Staphylococcus aureus (SA) in the mid-phase, maturation, and eradication phase. This indicated that LDNE had a concentration-dependent suppressive impact on the proliferation of Staphylococcus aureus biofilm